EF
VRTX icon

Empirical Finance’s Vertex Pharmaceuticals VRTX Stock Holding History

Empirical Finance’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.88M Sell
8,694
-17
-0.2% -$7.93K 0.18% 112
2025
Q4 		$3.95M Sell
8,711
-782
-8% -$337K 0.19% 102
2025
Q3 		$3.72M Buy
9,493
+487
+5% +$204K 0.18% 114
2025
Q2 		$4.01M Buy
9,006
+60
+0.7% +$27.6K 0.21% 101
2025
Q1 		$4.34M Buy
8,946
+133
+2% +$62K 0.26% 86
2024
Q4 		$3.55M Sell
8,813
-103
-1% -$47.7K 0.21% 94
2024
Q3 		$4.15M Buy
8,916
+190
+2% +$91.3K 0.24% 81
2024
Q2 		$4.09M Sell
8,726
-606
-6% -$263K 0.26% 79
2024
Q1 		$3.9M Buy
9,332
+314
+3% +$133K 0.24% 89
2023
Q4 		$3.67M Buy
9,018
+48
+0.5% +$17.7K 0.26% 85
2023
Q3 		$3.12M Buy
8,970
+865
+11% +$303K 0.23% 97
2023
Q2 		$2.85M Buy
8,105
+938
+13% +$316K 0.22% 97
2023
Q1 		$2.26M Buy
7,167
+345
+5% +$103K 0.21% 101
2022
Q4 		$1.97M Buy
6,822
+545
+9% +$166K 0.2% 105
2022
Q3 		$1.82M Buy
6,277
+1,032
+20% +$297K 0.22% 93
2022
Q2 		$1.48M Buy
5,245
+273
+5% +$73.1K 0.19% 102
2022
Q1 		$1.3M Buy
4,972
+530
+12% +$126K 0.15% 130
2021
Q4 		$975K Buy
4,442
+1,179
+36% +$229K 0.12% 158
2021
Q3 		$592K Buy
3,263
+186
+6% +$36.3K 0.09% 226
2021
Q2 		$620K Buy
3,077
+428
+16% +$89.5K 0.1% 218
2021
Q1 		$626K Hold
2,649
– – 0.11% 180
2020
Q4 		$626K Buy
2,649
+466
+21% +$107K 0.11% 180
2020
Q3 		$594K Buy
2,183
+485
+29% +$134K 0.13% 155
2020
Q2 		$493K Buy
1,698
+216
+15% +$58.6K 0.13% 145
2020
Q1 		$353K Buy
1,482
+533
+56% +$122K 0.11% 147
2019
Q4 		$208K Buy
+949
New +$192K 0.05% 199
2017
Q1 		– Sell
-104
Closed -$8K – 562
2016
Q4 		$8K Buy
+104
New +$8.46K 0.01% 440

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Empirical Finance's VRTX Position: Q1 2026 in Review

Empirical Finance reduced its Vertex Pharmaceuticals (VRTX) stake by 0.2% in Q1 2026, selling an estimated $7.93K and leaving 8,694 shares worth $3.88M. The position accounts for 0.18% of the portfolio, ranked #112.

Empirical Finance first reported a position in VRTX in Q4 2016 and has held it in 27 quarters since. The position peaked at $4.34M in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Empirical Finance held 8,694 shares of Vertex Pharmaceuticals worth $3.88M as of Q1 2026.
  • Empirical Finance sold 17 Vertex Pharmaceuticals shares in Q1 2026, an estimated $7.93K.
  • Vertex Pharmaceuticals made up 0.18% of Empirical Finance's portfolio in Q1 2026, its #112 holding.
  • Empirical Finance first reported a position in Vertex Pharmaceuticals in Q4 2016 and has held it in 27 quarters since.
  • Empirical Finance's Vertex Pharmaceuticals position peaked at $4.34M in Q1 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Empirical Finance's 13F filing for Q1 2026, filed 14 May 2026.